Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Ver em outros idiomas

Notícias

Relatório do Mercado Australiano de 14 de Fevereiro de 2011: Black Fire Minerals (ASX:BFE) Prestes a Adquirir Projeto de Tungstênio/ Cobre nos EUA

🕔2/14/2011 12:20:00 PM 30831

O Relatório do Mercado Australiano de 14 de Fevereiro de 2011 inclui: Black Fire Minerals Limited (ASX:BFE) prestes a adquirir 100% do Projeto avançado Tungstênio-Cobre Pilot Mountain em Nevada, EUA; Virax Holdings Limited (ASX:VHL) está desenvolvendo um novo produto para câncer de pele; Southern Cross Goldfields Limited (ASX:SXG) descobriu depósitos de ouro de alta qualidade e alta classificação na Austrália do Oeste; Prosperity Resources Limited (ASX:PSP) inicou a perfuração em busca de ouro na Indonésia.

Leia o artigo completo
###

133,990

  • Esta página foi acedida: (Últimos 7 dias: 15) (Últimos 30 dias: 52) (Desde Publicado em: 12087) 

Dados da empresa

    Fax
  • (03) 9853 5134 
  • Sector principais
  • Health & Pharm 
  • Indústria principais
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2024/11/14: Results of Annual General Meeting*
  • 2024/11/14: Chair and CEO AGM Presentation*
  • 2024/10/31: September 2024 Quarterly Update and Appendix 4C*
  • 2024/10/14: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/03: Change of Director's Interest Notice*
  • 2024/10/02: Notification of cessation of securities - PTX*
  • 2024/09/12: Prescient CEO to step down in early 2025*
  • 2024/09/05: PTX Presentation*
  • 2024/08/26: Appendix 4G and Corporate Governance Statement*
  • 2024/08/26: Appendix 4E and 2024 Annual Report*
*refer to company website